Novo Nordisk Faces Setback as CagriSema Declared Obsolete
Novo Nordisk's CagriSema drug trial results disappoint, leading to a significant drop in shares and raising questions about its market strategy.
Your source for breaking sports news, match results, transfers, and in-depth analysis.
Novo Nordisk's CagriSema drug trial results disappoint, leading to a significant drop in shares and raising questions about its market strategy.